NuPathe Inc said it terminated its takeover deal with Endo Health Solutions Inc and accepted an offer from Israel's Teva Pharmaceutical Industries Ltd . Teva offered to purchase the neurology drugs maker on Jan. 8 for $114 million plus milestone payments related to its Zecuity migraine treatment.
NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. Shares of PATH traded higher by 0.69% or $0.03/share to $4.38. In the past year, the shares have traded as low as $1.57 and as high as $4.49. On average, 585121 shares of PATH exchange hands on a given day and today's volume is recorded at 219326.
Source
